Marshall Urist compensation by year
Royalty Pharma Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $700,000 | $1,150,000 | $1,200,000 | $1,260,000 | $1,323,000 |
| Bonus | $2,850,000 | $3,200,000 | $3,360,000 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 |
| Option awards | $0 | $0 | $0 | $0 | $0 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $0 | $0 | $0 |
| Total | $3,550,000 | $4,350,000 | $4,560,000 | $1,260,000 | $1,323,000 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Royalty Pharma plc DEF 14A filed April 10, 2026, accession 0001140361-26-014239, and prior-year filings.
How this page was built: the Royalty Pharma plc filed document, accession 0001140361-26-014239. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 1,212,135 | $46,836,896 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Royalty Pharma plc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Royalty Pharma’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Terrance Coyne | Executive Vice President & Chief Financial Officer | $1,323,000 |
| George Lloyd | Senior Advisor; former Executive Vice President, Chief Legal Officer & Investments | $1,323,000 |
| Christopher Hite | Executive Vice President & Vice Chairman | $1,323,000 |
| Marshall Urist · this page | Executive Vice President, Research & Investments | $1,323,000 |
| Pablo Legorreta | Chairman and Chief Executive Officer | $937,500 |
Marshall Urist's compensation dossier, Royalty Pharma
You have read Marshall Urist's totals and holdings. The dossier adds each equity grant Royalty Pharma disclosed for Marshall Urist and Royalty Pharma's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Royalty Pharma compensation record
free company briefThis page is one person within Royalty Pharma's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Royalty Pharma proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Royalty Pharma's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Royalty Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.